Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates
Stoke Therapeutics reported Q1 2026 revenue of $6.2 million, a decrease from the prior year due to the recognition of a large one-time license fee in 2025, while maintaining a strong cash position of $411.0 million to fund operations into 2028. New 4-year longitudinal data from the Phase 1/2a open-label extension studies showed statistically significant improvements in cognition and behavior, along with durable seizure reductions for zorevunersen.
Key figures
- Revenue
- $6.2 million
- Net loss
- $50.0 million
- Rd expenses
- $39.7 million
- Atm proceeds
- $80.7 million
- Sga expenses
- $20.0 million
- Cash position
- $411.0 million
- Shares sold atm
- 2.6 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.